Assessing the diagnostic accuracy of routine hematoxylin and eosin, Alcian Blue/Periodic Acid-Schiff, and Giemsa stains in the detection of Helicobacter pylori in gastric biopsies

评估常规苏木精-伊红染色、阿利新蓝/过碘酸-雪夫染色和吉姆萨染色在胃活检中检测幽门螺杆菌的诊断准确性

阅读:1

Abstract

BACKGROUND: Hematoxylin and Eosin (H&E), Alcian Blue/Periodic Acid-Schiff (AB/PAS), and Giemsa stains are routinely used in the histopathological evaluation of gastric biopsies. However, comparative data on their diagnostic performance and cost-effectiveness in detecting Helicobacter pylori are limited. This study aimed to assess the feasibility of using H&E and AB/PAS as alternatives to Giemsa. METHODS: A retrospective study was conducted on 816 gastric biopsy cases collected between 2019 and 2021. Three slides (H&E, Giemsa, and AB/PAS) were previously prepared from each paraffin-embedded tissue sample and blindly evaluated by three independent examiners. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall diagnostic accuracy were calculated using 2×2 contingency tables. RESULTS: >H&E yielded a sensitivity of 51.6%, specificity of 74.4%, and diagnostic accuracy of 66.4% when compared to Giemsa as the reference standard. In comparison, AB/PAS exhibited a sensitivity of 45.9%, specificity of 73.2%, and an accuracy of 63.7%. When evaluating operational factors, H&E emerged as the most cost-effective and fastest method, while AB/PAS was associated with higher costs and longer processing times. Overall, Giemsa consistently demonstrated superior diagnostic performance across the assessed metrics, positioning it as the more reliable choice for H. pylori detection within this comparative framework. CONCLUSIONS: H&E shows potential for initial screening but its limited sensitivity prevents definitive diagnosis. AB/PAS proved less effective and economical. Giemsa maintained superior diagnostic performance. This study provides a comparative methodological assessment, suggesting H&E and Giemsa combinations could enhance detection efficiency and accuracy. Further prospective validation is needed before clinical implementation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。